Analysis of immunization time, amplitude, and adverse events of seven different vaccines against SARS-CoV-2 across four different countries

Background: Scarce information exists in relation to the comparison of seroconversion and adverse events following immunization (AEFI) with different SARS-CoV-2 vaccines. Our aim was to correlate the magnitude of the antibody response to vaccination with previous clinical conditions and AEFI. Methods: A multicentric comparative study where SARS-CoV-2 spike 1-2 IgG antibodies IgG titers were measured at baseline, 21-28 days after the first and second dose (when applicable) of the following vaccines: BNT162b2 mRNA, mRNA-1273, Gam-COVID-Vac, Coronavac, ChAdOx1-S, Ad5-nCoV and Ad26.COV2. Mixed model and Poisson generalized linear models were performed. Results: We recruited 1867 individuals [52 (SD 16.8) years old, 52% men]. All vaccines enhanced anti-S1 and anti-S2 IgG antibodies over time (p<0.01). The highest increase after the first and second dose was observed in mRNA-1273 (p<0.001). There was an effect of previous SARS-CoV-2 infection; and an interaction of age with previous SARS-CoV-2 infection, Gam-COVID-Vac and ChAdOx1-S (p<0.01). There was a negative correlation of Severe or Systemic AEFI (AEs) of naïve SARS-CoV-2 subjects with age and sex (p<0.001); a positive interaction between the delta of antibodies with Gam-COVID-Vac (p=0.002). Coronavac, Gam-COVID-Vac and ChAdOx1-S had less AEs compared to BNT162b (p<0.01). mRNA-1273 had the highest number of AEFIs. The delta of the antibodies showed an association with AEFIs in previously infected individuals (p<0.001). Conclusions: The magnitude of seroconversion is predicted by age, vaccine type and SARS-CoV-2 exposure. AEs are correlated with age, sex, and vaccine type. The delta of the antibody response only correlates with AEs in patients previously exposed to SARS-CoV-2. Registration number: ClinicalTrials.gov, identifier NCT05228912

La locura y sus versiones en la obra de J. Lacan II: locura y psicosis The madness and his versions in the J. Lacan work's II: madness and psychosis

Este trabajo presenta parte de las conclusiones del proyecto de investigación UBACyT P601: "Variaciones del concepto de locura en la obra de J. Lacan. Su incidencia en el diagnóstico diferencial neurosis-psicosis", aprobado y financiado para el período 2008-2010. Se aborda especialmente la cuestión problemática de su delimitación conceptual en la obra de Lacan, en la cual el término locura es empleado de diversos modos. Esta variedad se plasma en su articulación con distintos conceptos y con problemas clínicos de diversa índole. La presentación conjunta de estos usos permite obtener una visión bastante amplia de las ventajas que trae servirse de alguna de las versiones de la locura que se presentan en la obra de Lacan. En este trabajo se aplican a la articulación locura-psicosis, abordando no sólo la problemática conceptual en juego en lo atinente a alcanzar una definición más precisa de "locura", sino sobre todo el agudo problema clínico que presentan lo que podríamos designar "psicosis enloquecidas".<br>This paper presents some of the conclusions of the research project UBACyT P601: "Variations of the concept of madness in the work of J. Lacan. Its incidence in the differential diagnosis neurosis psychosis ", approved and funded for the period 2008-2010. It especially addresses the problematic issue of its conceptual delimitation in the Lacan work, in which the term "madness" is used in several senses. This variety is reflected in its theoretical concept articulation and several clinical issues. The whole presentation of these work allows a wider vision of the benefits that brings to use any of the versions of "madness" concept that arise in the work of Lacan. This work apply to the madness-psychosis articulation, addressing not only the conceptual issues, but also achieving a more precise definition of "madness"; and above of all it takes the big clinical problem in what we might call "mad psychosis"

Helicobacter pylori seroconversion in asymptomatic blood donors: A five-year follow-up

Several techniques have been developed to diagnose Helicobacter pylori infection and two noninvasive methods are available: carbon 13-urea breath test (UBT) and serology. Measurement of IgG serum antibodies by enzyme-linked immunosorbent assay (ELISA) is a reliable and inexpensive method for detection of infection. The aim of this study was to assess the seroconversion by different techniques after five to eight years. In 1990, 588 of 1010 asymptomatic donors were found to be seronegative by ELISA, based on an H. pylori whole-cell suspension lysate (sensitivity and specificity: 92% and 97%). In 1995 serum samples from 418 of 588 seronegative donors were collected and retested using the same antigen. 411 of 418 samples were frankly negative, and 7 donors were found to be seroconverted. This group of seven sera represents the object of the study. They were retested by ELISA and western blotting using a different antigen (NCTC). To standardize our techniques, sera from 43 H. pylori positive and 47 H. pylori negative patients according to culture, histology, urease test, and UBT were used. The cutoff for ELISA-NCTC was 0.53 AI (absorbance index) (mean value + 2 SD), and for western blotting was negativity for CagA or &lt;10 bands (sensitivity and specificity: 95% and 96%; 98% and 81% for ELISA and western blotting respectively). According to the results obtained in 1990 and 1995, seven donors were found to be seroconverted by ELISA using sonicated antigen; in five the seroconversion was confirmed by ELISA using NCTC antigen and in two there was concordance with WB. Four of the seven donors were contacted and asked to undergo UBT and a further serum sample was drawn to be reassessed in 1998. A seroconversion was found in all four donors by ELISA, while WB and UBT confirmed the seroconversion in only three of four donors. In conclusion the in-house ELISA used performed well compared to other theoretically better serologic assays and confirmed the low seroconversion rate for H. pylori infection in adult populations living in developed countries